Bo Ying, Abogen founder (Xi'an Jiaotong-Liverpool University)

Chi­na’s top mR­NA con­tender is ready to go. And Soft­Bank just led a cash in­fu­sion push­ing it over the $1B line

With Mod­er­na and BioN­Tech of­fer­ing a mod­el — in the US and Eu­rope, re­spec­tive­ly — for how mR­NA biotechs can en­joy a me­te­oric rise to prof­it and fame with just one suc­cess­ful Covid-19 vac­cine, a Chi­nese play­er is ready to put it­self on the map.

Abo­gen, which set a record just three months ago with a $720 mil­lion Se­ries C, has now raised an­oth­er $300 mil­lion as it pre­pares to file its vac­cine can­di­date for au­tho­riza­tion. Part­nered with Wal­vax and Chi­na’s mil­i­tary, ABO-028M first en­tered clin­i­cal test­ing in the sum­mer of 2020 and is now in Phase III tri­als in Mex­i­co, In­done­sia and Nepal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.